drugset / Trial / NCT01479127

Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease

NCT01479127

Phase 2 Completed 8 enrolled AbbVie Abbott Japan Co.,Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

To explore the safety, tolerability, pharmacokinetics and efficacy of ABT-SLV187 in advanced Parkinson's disease (PD) patients with severe motor complications. The complications of medical devices for the naso-jejunum (NJ) infusion system of ABT-SLV187 will also be investigated.

Timeline

Start
2011-10
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Background Levodopa Small molecule Other
Background Carbidopa Unknown 10 mg Oral
Background Levodopa Small molecule 100 mg Oral

Indications